Skip to main content
SpringerLink
Log in

New Therapeutic Options for Fragile X Syndrome

  • Pediatric Neurology (A Yeshokumar, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this review is to provide an overview of current research and clinical practice guidelines in fragile X syndrome (FXS) with regard to therapeutic approaches in the management of this condition. The authors summarize and discuss findings from relevant preclinical studies and results from clinical trials in human subjects with FXS. Additionally, we provide an outline of the basic framework for understanding and providing educational and psychosocial supports for these individuals.

Recent findings

Current treatments in FXS are largely symptom based and focused on managing associated psychiatric and behavioral co-morbidities. While data from animal studies has been promising in providing targeted treatments to correct the underlying deficits at the cellular level, there have not been as robust findings in human trials. There are several targeted treatments for FXS currently under development.

Summary

Individuals with FXS present with several behavioral challenges including anxiety, social withdrawal, ADHD, hyperarousal, self-injury, and aggression. Therapeutic services are often necessary, such as behavioral intervention, speech and language therapy, occupational therapy, and individualized educational support; adjunctive psychopharmacologic treatment is often helpful as well. It is important to address these symptoms and weigh the evidence for the use of medications that target the underlying neurobiology and pathophysiology of the syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Song F, Barton P, Sleightholme V, Yao G, Fry-Smith A. Screening for fragile X syndrome: a literature review and modelling study. 2003.

    Google Scholar 

  2. Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164(7):1648–58.

    Article  Google Scholar 

  3. Fu Y-H, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991;67(6):1047–58.

    Article  CAS  PubMed  Google Scholar 

  4. Pieretti M, Zhang F, Fu Y-H, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–22.

    Article  CAS  PubMed  Google Scholar 

  5. Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001;108(5):e88-e.

    Article  Google Scholar 

  6. Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 2004;129a(3):225–34.

    Article  PubMed  Google Scholar 

  7. Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard. 2008;113(1):44–53.

    Article  PubMed  Google Scholar 

  8. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008;113(6):427–38.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hagerman RJ, Rivera SM, Hagerman PJ. The fragile X family of disorders: a model for autism and targeted treatments. Curr Pediatr Rev. 2008;4(1):40–52.

    Article  CAS  Google Scholar 

  10. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J Dev Behav Pediatr. 2006;27(1):63–74.

    Article  PubMed  Google Scholar 

  11. Roberts JE, Miranda M, Boccia M, Janes H, Tonnsen BL, Hatton DD. Treatment effects of stimulant medication in young boys with fragile X syndrome. J Neurodev Disord. 2011;3(3):175–84.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sullivan K, Hatton D, Hammer J, Sideris J, Hooper S, Ornstein P, et al. ADHD symptoms in children with FXS. Am J Med Genet A. 2006;140(21):2275–88.

    Article  PubMed  Google Scholar 

  13. Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr. 2009;56(1):165–86.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Pan F, Aldridge GM, Greenough WT, Gan W-B. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc Natl Acad Sci. 2010;107(41):17768–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. • Davenport MH, Schaefer TL, Friedmann KJ, Fitzpatrick SE, Erickson CA. Pharmacotherapy for fragile X syndrome: progress to date. Drugs. 2016;76(4):431–45 This review offers a brief summary of the prevalence, phenotypic characteristics, genetic causes, and molecular functions of FMRP in the brain, discusses the most recent finding in FXS drug development, and summarizes FXS trials utilizing symptomatic treatment.

    Article  CAS  PubMed  Google Scholar 

  16. Ligsay A, Hagerman RJ. Review of targeted treatments in fragile X syndrome. Intractable Rare Dis Res. 2016;5(3):158–67.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Winarni TI, Schneider A, Borodyanskara M, Hagerman RJ. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile X syndrome. Case Rep Genet. 2012;2012:1–4.

    Article  Google Scholar 

  18. Boccuto L, Chen C-F, Pittman AR, Skinner CD, McCartney HJ, Jones K, et al. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013;4(1):16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. McDougle C, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):993–1000.

    Article  CAS  PubMed  Google Scholar 

  20. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74(2):285–99.

  21. Hagerman RJ, Fulton MJ, Leaman A, Riddle J. A survey of fluoxetine therapy in fragile X syndrome. Developmental Brain Dysfunction. 1994.

  22. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome—present and future. Ment Retard Dev Disabil Res Rev. 2004;10(1):42–8.

    Article  PubMed  Google Scholar 

  23. Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. Int J Pediatr. 2012;2012:1–11.

    Article  Google Scholar 

  24. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review. Autism Res Treat. 2012;2012:1–8.

    Article  Google Scholar 

  25. Consensus of the Fragile X Clinical & Research Consortium on Clinical Practices. Consensus of the Fragile X Clinical & Research Consortium on Clinical Practices: sleep in children with fragile X syndrome. . 2012.

  26. Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics. 2010;7(3):258–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378–90.

    Article  PubMed  Google Scholar 

  28. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293–302.

    Article  PubMed  Google Scholar 

  29. Liu Z, Smith CB. Lithium: a promising treatment for fragile X syndrome. ACS Chem Neurosci. 2014;5(6):477–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics. 1995;95(5):744–52.

    CAS  PubMed  Google Scholar 

  31. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30(1–2):377–92.

    Article  CAS  PubMed  Google Scholar 

  32. Torrioli M, Vernacotola S, Mariotti P, Bianchi E, Calvani M, De Gaetano A, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet. 1999;87(4):366–8.

    Article  CAS  PubMed  Google Scholar 

  33. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders. Eur Child Adolesc Psychiatry. 2005;14(1):34–40.

    Article  PubMed  Google Scholar 

  34. Hagerman R, Riddle J, Roberts L, Breese K, Fulton M. Survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct. 1995;8(4–6):336–44.

    Google Scholar 

  35. Turk CL, Heimberg RG, Orsillo SM, Holt CS, Gitow A, Street LL, et al. An investigation of gender differences in social phobia. J Anxiety Disord. 1998;12(3):209–23.

    Article  CAS  PubMed  Google Scholar 

  36. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(02):145–50.

    PubMed  PubMed Central  Google Scholar 

  37. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7.

    Article  CAS  PubMed  Google Scholar 

  38. Portera-Cailliau C. Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity? Neuroscientist. 2012;18(1):28–44.

    Article  CAS  PubMed  Google Scholar 

  39. Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12(3):584–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Oostra B, Nelson DL. Animal models of fragile X syndrome: mice and flies. Genet Instabil Neurol Dis. 2006:175–94.

  42. Willemsen R, Bontekoe CJ, Severijnen L-A, Oostra BA. Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet. 2002;110(6):601–5.

    Article  CAS  PubMed  Google Scholar 

  43. Berry-Kravis EM, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266–71.

    Article  CAS  PubMed  Google Scholar 

  44. Friedmann CT, Davis L, Ciccone P, Rubin R. Phase-II double-blind controlled-study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr Ther Res Clin Exp. 1980;27(2):144–51.

    Google Scholar 

  45. Jacquemont S, Curie A, Des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056, Sci Transl Med. 2011;3(64):64ra1-ra1.

  46. Bailey DB, Berry-Kravis E, Wheeler A, Raspa M, Merrien F, Ricart J, et al. Mavoglurant in adolescents with fragile X syndrome: analysis of clinical global impression-improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. J Neurodev Disord. 2016;8(1):1.

    Article  PubMed  Google Scholar 

  47. Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015;353(1):213–33.

    Article  CAS  PubMed  Google Scholar 

  48. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012;74(1):49–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, et al. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther. 2011;339(2):474–86.

    Article  CAS  PubMed  Google Scholar 

  50. Youssef EA, Berry-Kravis E, Czech C, Hagerman RJ, Hessl D, Wong CY, et al. Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results. Neuropsychopharmacology. 2018;43(3):503–12.

    Article  CAS  PubMed  Google Scholar 

  51. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010;30(29):9929–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. d'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009;1253:176–83.

    Article  CAS  PubMed  Google Scholar 

  53. Heulens I, D’Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012;229(1):244–9.

    Article  CAS  PubMed  Google Scholar 

  54. Olmos-Serrano JL, Corbin JG, Burns MP. The GABAA receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci. 2011;33(5):395–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. D'Hulst C, Heulens I, Van der Aa N, Goffin K, Koole M, Porke K, et al. Positron emission tomography (PET) quantification of GABAA receptors in the brain of fragile X patients. PloS One. 2015;10(7):e0131486-e.

    Article  CAS  Google Scholar 

  56. Braat S, d'Hulst C, Heulens I, De Rubeis S, Mientjes E, Nelson DL, et al. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle. 2015;14(18):2985–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ligsay A, Van Dijck A, Nguyen DV, Lozano R, Chen Y, Bickel ES, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord. 2017;9(1):26.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Isaacson JS, Hille B. GABAB-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron. 1997;18(1):143–52.

    Article  CAS  PubMed  Google Scholar 

  59. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012;4(152):152ra28-ra28.

    Article  CAS  Google Scholar 

  60. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152):152ra27-ra27.

    Article  CAS  Google Scholar 

  61. Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2017;9(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Schaefer TL, Davenport MH, Grainger LM, Robinson CK, Earnheart AT, Stegman MS, et al. Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety. J Neurodev Disord. 2017;9(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord. 2010;40(11):1412–6.

    Article  PubMed  Google Scholar 

  64. Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology. 2013;228(1):75–84.

    Article  CAS  PubMed  Google Scholar 

  65. Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tian J, Sanberg CD, et al. Peripheral biomarkers in autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int J Clin Exp Med. 2008;1(4):338–44.

    PubMed  PubMed Central  Google Scholar 

  66. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol. 2006;21(6):444–9.

    Article  PubMed  Google Scholar 

  67. Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161(8):1897–903.

    Article  CAS  Google Scholar 

  68. Bilousova T, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94–102.

    Article  CAS  PubMed  Google Scholar 

  69. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SMH, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010;115(5):433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Leigh MJS, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34(3):147–55.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, et al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 2013;27(10):956–63.

    Article  CAS  PubMed  Google Scholar 

  72. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99(11):7746–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Pilpel Y, Kolleker A, Berberich S, Ginger M, Frick A, Mientjes E, et al. Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice. J Physiol. 2009;587(4):787–804.

    Article  CAS  PubMed  Google Scholar 

  74. Eadie BD, Cushman J, Kannangara TS, Fanselow MS, Christie BR. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. Hippocampus. 2012;22(2):241–54.

    Article  CAS  PubMed  Google Scholar 

  75. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009;39(12):1629–35.

    Article  PubMed  Google Scholar 

  76. Osterweil EK, Chuang S-C, Chubykin AA, Sidorov M, Bianchi R, Wong RK, et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013;77(2):243–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Caku A, Pellerin D, Bouvier P, Riou E, Corbin F. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A. 2014;164a(11):2834–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eunice Kennedy Shriver Center, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA, 01655, USA

    Isha Jalnapurkar MD, David M. Cochran MD, PhD & Jean A. Frazier MD

  2. Department of Psychiatry, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA, 01655, USA

    Isha Jalnapurkar MD, David M. Cochran MD, PhD & Jean A. Frazier MD

Authors
  1. Isha Jalnapurkar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Cochran MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean A. Frazier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isha Jalnapurkar MD.

Ethics declarations

Conflict of Interest

Isha Jalnapurkar has no potential conflicts of interest relevant to this article.

David Cochran reports grants from Seaside Therapeutics, grants from Neuren, grants from Alcobra, during the conduct of the study; grants from F Hoffmann-La Roche Ltd., grants from Fulcrum Therapeutics, grants from Janssen Research and Development, LLC, outside the submitted work.

Jean Frazier reports grants from Seaside Therapeutics, grants from Neuren, grants from Alcobra, during the conduct of the study; grants from F. Hoffmann-La Roche Ltd., grants from Fulcrum Therapeutics, grants from Jansen Research & Development, LLC, grants from SyneuRx, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Neurology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jalnapurkar, I., Cochran, D.M. & Frazier, J.A. New Therapeutic Options for Fragile X Syndrome. Curr Treat Options Neurol 21, 12 (2019). https://doi.org/10.1007/s11940-019-0551-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-019-0551-8

Keywords

Search

Navigation